Semaglutide therapy for obesity achieves significant weight and body fat loss; real-world discontinuation patterns explored.
Discontinuation of Semaglutide Therapy for Obesity Management.
Abstract
Semaglutide therapy for obesity led to a median 8.0 kg weight loss and reduced body fat percentage, with real-world discontinuation patterns investigated.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
